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Abstract
Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene.
Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was
standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom
of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis
buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for
mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous
fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system
traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a
safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a
larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product
derived from animal venom.
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Background
The first research studies on hemostatic agents and adhe-
sives date back to World War II, when fibrin glue was pro-
posed. In that time, a mixture of human fibrinogen and
thrombin was applied to the affected aera. In 1970, given
that the basic principles for extracting fibrinogen-rich cryo-
precipitate and coagulation factors were already known, the
concept of fibrin glue was reevaluated. Since that point, a
new adhesive has been standardized with the following
composition: fibrinogen-rich human cryoprecipitate, bovine
thrombin and calcium chloride as the diluent. This sealant
was successfully commercialized for years [1, 2].
In 1978, the U.S. Food and Drug Administration
(FDA) suspended its commercialization due to the
possibility of the transmission of infectious diseases, car-
ried via products derived from human blood [3, 4].
In order to overcome these difficulties, in the 1990s
the Center for the Study of Venoms and Venomous Ani-
mals (CEVAP) at São Paulo State University (UNESP)
initiated studies to achieve the standardization of a new
heterologous fibrin sealant (HFS). After several experi-
ments, a new sealant was proposed, which was com-
posed of a fibrinogen-rich cryoprecipitate extracted from
the blood of the buffalo Bubalus bubalis in association
with a serine protease (a thrombin-like enzyme) ex-
tracted from Crotalus durissus terrificus venom [5–8].
The active ingredient of this new heterologous fibrin
sealant mimics the final step of the coagulation cascade.
So, a thrombin-like enzyme acts upon the fibrinogen
molecule, transforming it into fibrin monomers that
polymerize in the presence of calcium to form a stable
clot with adhesive, hemostatic and sealant effects [8, 9].
Figure 1 shows the blood-clotting cascade in three dif-
ferent pathways, with human thrombin, bovine thrombin
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and serine protease extracted from Crotalus durissus
terrificus venom [9]. Figure 2 shows a stable network of
fibrin formed from a mixture of animal cryoprecipitate
with serine protease extracted from snake venom, ob-
served by electron microscopy [10].
Composition of the heterologous fibrin sealant
Fraction I: serine protease (gyroxin)
Molecular structure
The composition of the venom from Crotalus duris-
sus terrificus snakes is complex and constituted of
enzymes, toxins and peptides. Since the 1980s,
several authors have studied, isolated and purified
serine proteases including gyroxin, a thrombin-like
enzyme extracted from the venom of Crotalus duris-
sus terrificus [11–15]. Electrophoretic analysis veri-
fied that this enzyme is a single-chain type, with an
estimated molecular mass of 34 kDa and maximum
stability at pH 8.0, and does not present alteration
by freezing or thawing. Its maximum enzymatic ac-
tivity occurs at pH 4.0, being resistant to treatment
at 40 ° C for 15 min.
Fig. 1 a The final common pathway of the human blood-clotting cascade. b The effect of bovine thrombin on human fibrinogen. c The effect of
a serine protease (thrombin-like enzyme) extracted from snake venom on animal fibrinogen forming a stable fibrin polymer. Reprinted from “A
new fibrin sealant from Crotalus durissus terrificus venom: applications in medicine” by LC Barros et al., J Toxicol Environ Health B Crit Rev, 2009,
12(8), 553–71 [9]. Copyright by Taylor & Francis LLC (http://www.tandfonline.com). Reprinted with permission
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Theoretical molecular modeling of this serine protease
extracted from Crotalus durissus terrificus venom was ac-
complished via the program Modeller and visualization of
the model by the program PyMOL. In this manner, Fig. 3
shows the structural model, which was revealed as a
monomeric globular structure, presenting two α-helix
structures (red) containing the residues 146–152 and
215–227, two β-barris structures formed by six antiparallel
sheets and loops (green), five disulfide bridges (blue) and a
catalytic triad (orange) [16, 17].
Due to its enzymatic activity, similar to thrombin, the
serine protease acts on human and animal fibrinogen,
cleaving the α-chain proximal to the N-terminal. The re-
sultant fibrin monomers were polymerized in an intense
stable network (Fig. 2) in contrast to that traditionally
produced by thrombin.
Isolation and structural elucidation
Venom from Crotalus durissus terrificus snakes (Fig. 4)
was milked at CEVAP and pooled according to good
manufacturing practices (GMP). All the snakes are micro-
chipped to ensure the traceability of the venom lots used
in the composition of heterologous fibrin sealant. After fil-
tration and lyophilization, the venoms are stored in the
Venoms Bank of CEVAP.
To isolate the serine protease (gyroxin), a low-pressure
liquid chromatography system was employed, specifically
the model Äkta Pilot® (GE HealthCare Life Science,
Sweden) and the software Unicorn® 6.3 controlled the
data acquisition. All reagents and salts utilized were of
HPLC grade, and the Milli-Q water used was obtained
in a Milipore® ultra-purifier (Fig. 5).
Fifteen grams of lyophilized venom from Crotalus duris-
sus terrificus was suspended in 200 mL of the buffer 0.05
M Tris-HCl pH 7.4. This was applied in an AxiChrom
100/300® chromatographic column (100 mm x 300 mm x
350 mL) (GE HealthCare Life Science, Sweden) encased
with affinity resin Benzamidine Sepharose 6B® (GE
HealthCare Life Science, Sweden) previously equilibrated
with 525 mL of 0.05 M Tris-HCl pH 7.4 buffer (buffer 1).
The sample was eluted with 525 mL of 0.05 M Tris-HCl
pH 7.4 (buffer 1), followed by 525 mL of 0.05 M Tris-
HCl/0.5 M NaCl pH 7.4 (Buffer 2) and 1,050 mL of gly-
cine 0.02 M pH 3.2 (buffer 3). The flow utilized was 10
mL/min and collected 25 mL/tube. The elution was moni-
tored at an absorbance of 280 nm.
This purification process generates a single fraction
whose purity is evaluated by N-terminal sequences
(EDMAN) and mass spectrometry.
Fig. 3 Theoretical molecular modeling of gyroxin accomplished
using Modeller and PyMOL programs. This serine protease has two
α-helix structures (red) containing the residues 146–152 and 215–
227, two β-barris structures formed by six antiparallel sheets and
loops (green), five disulfide bridges (blue) and a catalytic
triad (orange) Fig. 4 Crotalus durissus terrificus snake
Fig. 2 Stable fibrin network visualized in an electron microscope
(4,000×). Reprinted from “A new fibrin sealant as a three-dimensional
scaffold candidate for mesenchymal stem cells” by VPO Gasparotto et al.,
Stem Cell Res Ther, 2014, 5(3), 78 [10]. Copyright by VPO Gasparotto et al.
Reprinted with permission
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Figures 6 and 7 show, respectively, the comparison of
N-terminal sequence of gyroxin with other thrombin-
like snake toxins and their molecular mass by ESI mass
spectrometry.
Biological activity
In 2011, Barros et al. [9, 18] evaluated the coagu-
lant activity of a serine protease isolated from Cro-
talus durissus terrificus venom, which was able to
induce the formation of a fibrin network and con-
sequently the formation of a stable clot at different
concentrations.
Coagulant activity was studied at three different pH,
namely: 4.0, 6.0 and 7.4. At each of them, the minimum
coagulant dose (MCD) was verified and defined as the
quantity at which a certain enzyme is capable of coagu-
lating 200 μL of plasma in 60 s [15]. At pH 4.0, the
MCD was 0.037 μg/μL of plasma, versus 0.015 μg/μL at
pH 6.0 and 0.021 μg/μL at pH 7.4. Table 1 and Fig. 8
display the MCD at pH 7.4.
The serine protease coagulant activity at pH 7.4 was
also confirmed through dose-dependent activity evalu-
ated to obtain the MCD. For potential regression ana-
lysis, the MCD was determined at 0.021 μg/μL of
human plasma, as shown in Fig. 9.
It must be emphasized that the statistical analysis did
not present a difference in the comparison of serine pro-
tease activity at pH 6.0 versus pH 7.4. These results lead
to the conclusion that the best activity of the enzyme is
found at between pH 6 and 7.4, values close to the
optimum pH for blood-thrombin activity, which is 7.3
and varies in blood between 7.35 and 7.45 [18].
Fraction II: cryoprecipitate
Cryoprecipitate is the insoluble fraction, a cold precipi-
tate of frozen fresh plasma (FFP) from Bubalus bubalis
buffalos. It contains fibrinogen, factor VIII (F VIII),
Willebrand factor (F vW), factor XIII (F XIII) and fibro-
nectin [19, 20]. It must contain at least 80 units of factor
VIII and between 150 and 250 mg of fibrinogen. Each
Fig. 5 Affinity liquid chromatography of Crotalus durissus terrificus crude venom with Benzamidine-Sepharose 6B resin (column AxiChrom 100/
300® (100 mm × 300 mm × 350 mL). The column was equilibrated with 0.05 M Tris-HCl pH 7.4 (buffer 1). Sample: 15 g of crude venom was
suspended in buffer 1. The sample elution was carried out with 525 mL of buffer 1 followed by 525 mL of 0.05 M Tris-HCl/0.5 M NaCl pH 7.4
(buffer 2) and 1,050 mL of 0.02 M glycine pH 3.2 (buffer 3), at flow rate 10 mL/min, and collected 25 mL/tube. Absorbance 280 nm
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unit has a volume from 10 to 20 mL, which must be
stored at –20 ° C and has a shelf life of one year.
In 1995, Iuan et al. [5] proposed for the first time a new
fibrin sealant constituted of a serine protease extracted
from the venom of Crotalus durissus terrificus and human
cryoprecipitate. The new product was compared with the
commercial sealant in relation to the repair of sciatic
nerves in Wistar rats. The anatomopathological analyses
found similar results between the two products. Aiming at
preventing infectious diseases transmitted by human
Fig. 7 LC-MS by ESI-ToF mass spectra (MicroQ-ToF III, Bruker Daltonics®). a Different protonated forms of gyroxin from Crotalus durissus terrificus. b
Deconvoluted mass spectrum showing [M + H]+1 = 29.472 m/z. Molecular mass of this serine protease is 29.473 Da
Fig. 6 Comparison between the N-terminal sequences by multiple alignment by MultiAlin program. The first sequence shows the serine protease
purified in this study, followed by the sequences deposited in the NCBI such as: B2.1 (thrombin-like enzyme from Crotalus durissus terrificus venom);
crotalase (thrombin-like enzyme from Crotalus adamanteus venom); gyroxin analog (thrombin-like enzye from Lachesis muta muta venom) and ancrod
(thrombin-like enzyme from Agkistrodon rhodostoma). The red letters indicate high similarity (90%) and blue a low similarity level (50%). The black letters
indicate no similarity
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blood, Thomazini-Santos et al. [21] in 1998 proposed for
the first time to replace fibrinogen extracted from human
blood with that from buffaloes. These same authors [21]
evaluated the cryoprecipitate level of diverse animals and
compared them with that extracted from human blood.
They observed that buffaloes presented the highest fi-
brinogen levels, as shown in Table 2. Due to the good per-
formance of the cryoprecipitate extracted from buffalos,
these animals have been selected as the ideal donors.
In Brazil, the following four buffalo breeds are recog-
nized by the Brazilian Association of Buffalo Breeders:
mediterrâneo, murrah, jafarabadi (river buffalo) and
carabao (swamp buffalo). The murrah breed, Bubalus
bubalis, of Indian origin has been raised at the Lageado
Experimental Farm, UNESP campus in Botucatu, for
more than 30 years [22].
In order to ensure that this bioproduct contains no sub-
stance foreign to the human body, it is necessary to select
and certify the donors. Therefore, sanitary management is
mandatory for good economic results, which includes the
following actions: annual vaccination against foot-and-
mouth disease, brucellosis and rabies; systematic deworm-
ing; measures for hygiene and asepsis; practices of isolation
and quarantine; protection of animals against vectors of
transmissible diseases; diagnostic serological tests against
brucellosis and leptospirosis; an annual hypersensitivity test
against tuberculosis (tests of tuberculinization and of Man-
toux or PPD); as well as frequent clinical exams performed
by an experienced veterinary physician. These actions are
recommended by the Department of Animal Health of the
Secretariat for the Defense of Agribusiness and Livestock
Raising in the Ministry of Agriculture, Livestock and Food
Supply (MAPA) and by the World Health Organization,
and are in continuous execution by the abovementioned
team [23–29].
Despite all these precautions, these animals can still
pose a risk to human health due to transmission of
spongiform encephalopathies (TSEs), also known as prion
diseases, or as “mad cow” [29]. They are fatal neurodegen-
erative diseases that include scrapie in sheep, a bovine
spongiform encephalopathy (BSE) and Creutzfeldt-Jakob
disease (CJD) in humans. In buffalos, the transmission can
occur through the consumption of previously infected tis-
sue that is used in the feed manufacturing, particularly
nerve tissue. In suspicious cases, the necropsy becomes
the highest priority, followed by anatomical-pathological
analysis. Researchers at CEVAP in partnership with the
Center for Stable Environmental Isotopes, in the Botucatu
Biosciences Institute of UNESP, developed a globally pio-
neering technique of isotopic tracers based on the dosing
of carbon isotopes (13C) and nitrogen (15N) in sheep and
buffaloes [30, 31]. After its standardization, this technique
was tested in animals of the abovementioned herd, show-
ing an absence of animal protein ingestion, which indir-
ectly indicates that the buffalo donors of cryoprecipitate
were potentially free of mad cow disease.
The growing concern with the rapid identification and
resolution of sanitary problems in livestock has increased
the interest in the study of biomarkers. Recent research
has shown that the quantification of acute-phase proteins
in blood can offer useful information for early diagnosis,
prognosis and monitoring of diseases [32]. These proteins
are considered not only potential indicators of inflamma-
tory disease or contagious infections, but also an import-
ant tool in slaughterhouses to ensure food safety [33, 34].
Fig. 8 Coagulant activity: a fibrin clot formed after incubation of human plasma with serine protease; b detail of fibrin network
Table 1 Serine protease concentrations employed to evaluate
the clotting time, the mean of three measures, the standard
deviation and standard error of the mean for a 95% confidence
interval at pH 7.4
Concentration (μg) Mean (seconds) Standard deviation Standard
error of
the mean
3 84 ±3.60 2.08
5 50.7 ±0.57 0.33
10 32.7 ±0.57 0.33
15 20 ±0.0 0.0
20 14.7 ±0.57 0.33
25 13.3 ±0.57 0.33
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The concentrations of these proteins, which remain
circulating for long periods, depend on the severity of
the dysfunction. Therefore, their quantification is an es-
sential tool to evaluate the presence and severity of the
inflammatory process, in contrast to the cytokines that
remain circulating for short periods and whose measure-
ment is onerous [35].
The first response of the organism to immunological
stress is a non-specific release of cytokines that are me-
diators in the variation of acute-phase proteins [34, 35].
Through the influence of interleukins 1 and 6 (IL-1, IL-
6) and of tumor necrosis factor (TNF-α), the hepatic
cells augment or diminish the synthesis and the secre-
tion of certain proteins. The response occurs immedi-
ately after a lesion or disease, declining within one or
two days. The acute-phase proteins can be divided into
two groups: negative and positive. The negative proteins
are those that diminish the concentration when an
acute-phase response occurs – and include albumin and
transferrin, while the positive ones have their level ele-
vated when there is an acute-phase response. In the lat-
ter case we have an increase in circulating C-reactive
protein (CRP), glycoprotein-1 acid, antitrypsin-1,
antichemotrypsin-1, serum amyloid A, ceruloplasmin,
haptoglobin, macroglobin-2, fibrinogen and component
C3 of the complement system [34, 36, 37].
For ruminants, haptoglobin has been described as the
most important and reliable marker [32, 33]. Thus, the
standardization of acute-phase biomarkers (fibrinogen
and haptoglobin) and the clinical evaluation prior to
blood donation permit the presumptive diagnosis of pos-
sible diseases and the removal of the donor animal to
ensure the extraction of a safe bioproduct.
A rigorous protocol was applied in order to maintain
biosecurity and the traceability of cryoprecipitate, as
follows:
 In the herd of buffalos:
➢ microchipping permitting traceability a
posteriori;
➢ annual vaccination control against rabies,
brucellosis and foot-and-month disease;
➢ application and annual evaluation of the
tuberculin;
➢ control of spongiform encephalopathy (mad
cow disease) by means of isotopic analysis;
➢ nonspecific presumptive diagnosis of diseases
for selection of ideal donors by means of
haptoglobin and fibrinogen biomarkers.
 In blood collection:
➢ utilizing quadruple bag with filters in a line
similar to those employed for humans;
➢ transporting the bags with blood in refrigerated
boxes to the processing laboratory;
➢ applying techniques to evaluate fibrinogen
levels and the factors V, VIII and von Willebrand;
Table 2 Comparison of fibrinogen concentration in mg% in human, bovine, equine, ovine and buffalo blood
Mean fibrinogen concentration in cryoprecipitate (mg%)
Human (N = 12) G1 Bovine (N = 9) G2 Equine (N = 10) G3 Ovine (N = 10) G4 Buffalo (N = 7) G5
375.50 ± 70.95 218.33 ± 9.76 240.80 ± 72.03 267.70 ± 25.42 664.00 ± 11.96
Statistics: G1 × G2 × G3 × G4 × G5, F = 120.26, p < 0.001, G5 > G1 > (G2 = G3 = G4)
Fig. 9 Evaluation at pH 7.4 of the minimum coagulant dose (MCD) of the serine protease by potential regression analysis y = 220.13x-0,879, R2 = 0.9899
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➢ preventing possible contaminations of the bags
utilizing for quality control animal blood culture
and of the bags in Bactec® for aerobic and
anaerobic bacteria and Bactec Myco-F Lytic® for
fungi.
Finally, analytical methods with singular characteristics,
such as higher sensitivity, resolution and reproducibility
were employed with a clinical proteomic approach [38].
Two-dimensional electrophoresis (2D) was used for isolat-
ing and identifying proteins by means of their molecular
masses and isoelectric points in polyacrylamide gel, and
electrospray-type mass spectrometry was used for sequen-
cing peptides and proteins and identifying their biological
function. Figure 10 shows the total protein profile of cryo-
precipitate extracted from buffalos presenting the different
forms of fibrinogen, evidenced for better visualization,
since this protein is the main molecule responsible for
stable fibrin clot formation. There are three observable
classes of fibrinogen denominated: β-chain fibrinogen,
from α and partial forms of α-chain fibrinogen, totaling 40
different forms of the molecule.
Fig. 10 Bubalus bubalis cryoprecipitate protein profile (2D-SDS-PAGE) showing 40 different forms of fibrinogen molecules
Fig. 11 Packaging and vials approved only for clinical research use
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In sum, the cryoprecipitate extracted to be applied as
a new heterologous fibrin sealant standardized by
CEVAP is a product that is safe and free from undesir-
able substances. The formulation, as well as its storage,
handling and dosage are described in detail in the inter-
nationally required patents (PCT/BR2015/000065 and
PCT/BR2015/000064) [39].
The human use of heterologous fibrin sealant
The heterologous fibrin sealant, widely studied experimen-
tally, is now in a phase I/II clinical trial for the treatment of
chronic venous ulcers. Herein, we briefly describe the
methodology utilized for manufacturing this new biomedi-
cine that possesses vast potential to replace the human con-
stituents utilized in commercial sealants currently available
on the market. This product has undergone more than 20
years of development and due to its novelty and originality,
it represents a success story in the context of World
Toxinology, mostly in the southern hemisphere.
Until the present, two phase I/II clinical trials (called
Sealant I and Sealant II) have been proposed for evalu-
ating the treatment of chronic venous ulcers. For this
purpose, four batches of sealant were produced for ap-
plication in ten participants in the first project already
concluded (Sealant I) and, in 30 participants in the sec-
ond, which is now underway (Sealant II).
For the determination of the protein concentration of
serine protease (gyroxin) utilized in the finished product,
protein dosing was performed via direct reading at 280
nm utilizing a NanoView® spectrophotometer (GE Health-
care, USA). This apparatus quantifies the concentration of
proteins according to the law of Lambert-Beer [40]. In
this manner, the gyroxin quantity sufficient for poly-
merizing the fibrin contained in 1 mL of cryoprecipitate
was defined for each 2 mL-dose of fibrin sealant. This
quantity of polymer should cover an ulcer with a max-
imum size of 60 cm2. A 1 mL vial of cryoprecipitate
contains, in addition to fibrinogen, the following coagu-
lation factors: factor V, VIII and von Willebrand. The
diluent vial contains 0.6 mL of a stable solution of cal-
cium chloride. The details of this composition are de-
scribed in the submitted patents [39].
Figures 11 and 12 demonstrate the product packaged
for clinical research, with attention to the protocols of
the National Health Surveillance Agency (ANVISA) in
Brazil, as well as its preparation for application in ulcers
of the participants (ethics approval CONEP-CAAE:
19006813.4.1001.5411).
Fig. 12 a Application of the product utilizing a double-outlet syringe with mixer at its end. b Polymerized product covering an ulcer
Fig. 13 A 70 year-old female had an ulcer for two years. a Visit 0 – area of the ulcer was 17.1 cm2. b Visit 6 – wound healed
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The objectives of the Sealant I project were already
achieved, namely: to study safety and most appropriate
dose of the new heterologous fibrin sealant for treating
chronic venous ulcers.
Figures 13 and 14 show the evolution and ulcers healing in
two participants, before (V0) and at the end of treatment.
The new heterologous fibrin sealant is a safe and clin-
ically promising candidate for treating chronic venous
ulcers. A multicenter clinical trial, phase II/III, with a
larger number of participants will be performed to prove
the efficacy of the product [41]. A six-minute video is
provided showing an overview of the production and ap-
plication of the fibrin sealant (Additional file 1) (avail-
able at: https://youtu.be/y6ho6M0amA8).
Conclusions
The homologous commercial fibrin sealant has been
used with success since the 1970s. Nowadays, its appli-
cation has been consolidated in surgical procedures as
an efficient method to avoid suturing, decrease recov-
ery time and increase the success rate. Its indications
are well defined and proven through a systematic re-
view of studies and meta-analysis [42–45]. Among the
unsolved problems, especially in biopharmaceutical
production, are the high costs and transmission of in-
fectious diseases by human blood [3, 4]. The new heter-
ologous fibrin sealant, composed primarily of extracted
animal products, has low production costs and does
not transmit infectious diseases. Standardized for over
20 years by a consortium of Brazilian researchers, sev-
eral preclinical studies and clinical trials have already
been completed. Thus, preclinical trials applying the
product in the peripheral nervous and musculoskeletal
systems [46–56] and as a scaffold for stem cells have
been studied extensively [57–60]. Trials in plastic
surgery skin repair [61], periodontal surgery [62–64]
and in chronic venous ulcers have also been performed
[41, 65]. In addition to treating chronic venous ulcers,
further clinical trials, especially ones linked to the ner-
vous system and to skeletal muscle, will allow for a
more precise use.
Additional file
Additional file 1: The video shows a six-min overview of the production
and application of the fibrin sealant derived from snake venom and buffalo
blood (available at https://youtu.be/y6ho6M0amA8). (DOCX 11 kb)
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